Oncology Based In-vivo CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft), By Region and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2018-2028

Market Size (2022)

USD 1.24 Billion

CAGR (2023-2028)

8.29%

Fastest Growing Segment

Solid Tumour

Largest Market

North America


Market Overview

Oncology Based In-vivo CRO Market has valued at USD 1.24 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.29% through 2028. The oncology-based in vivo Contract Research Organization (CRO) market is a dynamic and rapidly evolving sector at the intersection of healthcare, research, and pharmaceutical development. Fueled by the escalating prevalence of cancer and the pursuit of innovative therapies, this market plays a pivotal role in advancing our understanding of cancer biology and accelerating the development of novel treatments. With an emphasis on conducting preclinical and clinical trials in living organisms, these specialized CROs serve as indispensable partners for pharmaceutical and biotechnology companies seeking to bring effective oncological therapies to the market. The market's growth is propelled by factors such as groundbreaking technological advancements, including cutting-edge imaging techniques and personalized medicine approaches.

Key Market Drivers

Rising Prevalence of Cancer

The relentless rise in cancer incidence has propelled the oncology-based in vivo Contract Research Organization (CRO) market into a dynamic phase of growth. As cancer continues to exert an alarming global impact, there is an escalating demand for swift and precise solutions, spurring a surge in research and development activities. This surge, in turn, fuels the need for specialized services provided by in vivo CROs. With the intricacies of cancer biology and treatment modalities constantly evolving, pharmaceutical and biotechnology companies increasingly rely on these CROs to conduct intricate preclinical and clinical studies. The complexity of cancer research requires a multidisciplinary approach, and in vivo CROs are adept at providing the essential tools, expertise, and resources to accelerate the development of innovative therapies. As personalized medicine gains traction, tailoring treatments to individual genetic profiles necessitates sophisticated research techniques offered by these CROs. Moreover, the competition to bring novel therapies to the market drives the outsourcing trend, as companies seek to streamline operations and enhance efficiency. In a landscape characterized by rapid advancements in genomics, imaging technologies, and data analytics, in vivo CROs play an indispensable role in facilitating groundbreaking discoveries. Ultimately, the surging tide of cancer cases has not only heightened the demand for effective treatments but has also become a powerful catalyst for the expansion and diversification of the oncology based in vivo CRO market, propelling it into a pivotal position at the forefront of the fight against this formidable disease.

Advancements in Cancer Research

The ever-evolving landscape of cancer research is wielding a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. With each stride in our understanding of cancer biology, genetics, and treatment mechanisms, the demand for highly specialized research services provided by in vivo CROs surges. Advancements in areas such as immunotherapy, targeted therapies, and precision medicine have transformed the oncology field, necessitating more intricate and tailored studies. In vivo CROs possess the expertise and cutting-edge technologies required to conduct complex preclinical and clinical investigations that align with these breakthroughs. As new avenues for treatment emerge, pharmaceutical and biotechnology companies are increasingly turning to these CROs to expedite drug development processes and ensure the safety and efficacy of their therapies. The intricate interplay between genetics, tumor microenvironments, and therapeutic responses mandates a comprehensive and multidimensional approach to research, and in vivo CROs are poised to fulfill this role adeptly. Furthermore, the competitive drive to be at the forefront of innovative cancer treatments has spurred companies to outsource research activities to specialized partners, contributing to the expansion of the CRO market. In an era characterized by rapid scientific progress, the symbiotic relationship between advancements in cancer research and the growth of the oncology based in vivo CRO market is poised to forge a transformative path forward in the fight against cancer.


Download free Sample Report

Key Market Challenges

Complexity of Cancer Research

The intricate nature of cancer research stands as a formidable obstacle impeding the growth of the oncology-based in vivo Contract Research Organization (CRO) market. The multifaceted challenges posed by the diversity of cancer types, intricate genetic variations, and evolving treatment paradigms demand a level of specialized expertise that few can provide. Conducting accurate and comprehensive in vivo studies that mirror the complex reality of cancer within living organisms requires sophisticated methodologies and equipment, which can strain the resources of both CROs and their clients. Moreover, the need to keep abreast of rapidly advancing scientific discoveries adds another layer of complexity. Ensuring that in vivo studies effectively capture the intricate interplay of genetic factors, tumor microenvironments, and treatment responses necessitates a multidimensional approach that requires not only cutting-edge technologies but also a deep understanding of cancer biology. As such, the complexity of cancer research can hinder the growth of the in vivo CRO market by limiting the pool of experts, increasing costs, and elongating project timelines, thereby underscoring the critical need for sustained innovation and collaboration within the field.

High Costs

The soaring costs associated with oncology-based in vivo Contract Research Organization (CRO) services pose a significant barrier to the market's expansion. Conducting comprehensive in vivo studies demands advanced equipment, skilled personnel, and substantial resources, resulting in elevated project costs. These expenses can deter smaller pharmaceutical and biotech companies, as well as research institutions with limited budgets, from accessing the expertise and services offered by in vivo CROs. Moreover, the high costs can also lead to increased pricing for services, potentially making them unaffordable for certain clients. This financial strain can curtail research and development efforts, slow down the pace of drug discovery, and limit the industry's ability to accommodate a broader range of projects. As such, addressing the issue of high costs is pivotal for fostering a more accessible and vibrant oncology based in vivo CRO market, enabling diverse entities to harness the specialized capabilities required to advance our understanding and treatment of cancer.

Key Market Trends

Personalized Medicine

The paradigm shift towards personalized medicine is exerting a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As medical science increasingly recognizes the unique genetic and molecular profiles that underlie individual patients' responses to treatments, the demand for highly tailored research and preclinical studies has surged. In vivo CROs are at the forefront of this transformative trend, enabling the creation of animal models that closely mimic patients' genetic characteristics. These models allow for precise evaluations of potential therapies, predicting their effectiveness and potential side effects in specific patient populations. The intricate interplay between genetic factors, tumor microenvironments, and treatment responses necessitates nuanced research methodologies, and in vivo CROs possess the expertise and cutting-edge technologies required to execute such studies. With the goal of developing treatments that are optimally effective and minimally toxic for each patient, pharmaceutical and biotech companies are increasingly relying on in vivo CROs to conduct studies that bridge the gap between preclinical research and clinical trials. As personalized medicine gains momentum, the strategic role of in vivo CROs in shaping the landscape of oncology research and therapy development becomes ever more pronounced, solidifying their pivotal contribution to the advancement of precision cancer care.

Digitalization and Data Analytics

The rapid integration of digitalization and data analytics is wielding a transformative impact on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As cancer research becomes increasingly data driven, in vivo CROs are leveraging advanced technologies to enhance the efficiency, accuracy, and depth of their studies. Real-time monitoring, high-resolution imaging, and sophisticated data analysis tools enable a comprehensive understanding of cancer biology, treatment responses, and disease progression. This digital revolution empowers researchers to extract meaningful insights from complex datasets, identifying subtle patterns and correlations that were previously elusive. In vivo CROs equipped with these capabilities can offer a comprehensive view of how potential therapies interact with living organisms at molecular and cellular levels, paving the way for more informed decision-making during drug development. Additionally, the integration of digital tools facilitates remote monitoring and collaboration, allowing researchers to conduct studies across geographical boundaries. This not only accelerates research timelines but also opens doors to global partnerships and client collaborations. As the demand for precise and data-rich insights in oncology research intensifies, in vivo CROs adept in harnessing digitalization and data analytics are poised to drive advancements in our understanding of cancer and propel the development of more effective therapies, solidifying their pivotal role in the dynamic landscape of oncology research.

Segmental Insights

Indication Insights

With a 47.08% market share in 2022, the solid tumors segment dominates the Oncology Based In-vivo CRO market and is predicted to continue expanding over the coming years. Solid tumors have emerged as dominant players in the oncology-based in vivo Contract Research Organization (CRO) market due to their prevalence and complex nature. These tumors, characterized by their cohesive mass of cells, represent a significant portion of cancer cases, driving the demand for specialized research services provided by in vivo CROs. Given the intricate interplay of genetic mutations, microenvironmental factors, and treatment responses within solid tumors, preclinical studies conducted by in vivo CROs are essential for evaluating potential therapies. As the understanding of solid tumor biology and targeted therapies advances, pharmaceutical and biotech companies increasingly rely on these CROs to conduct comprehensive studies that inform clinical trial design and decision-making. The specialized expertise of in vivo CROs in creating accurate animal models and conducting sophisticated analyses aligns with the intricacies of solid tumor research, establishing them as pivotal contributors in advancing our ability to combat these formidable diseases.

Model Insights

In 2022, the Oncology Based In-vivo CRO market was dominated by the Syngeneic segment, which held the largest revenue share of 70.82%. Syngeneic models have surged to dominance in the oncology-based in vivo Contract Research Organization (CRO) market due to their exceptional relevance and utility in cancer research. These models involve transplanting tumor cells into animals with intact immune systems from the same species, enabling the study of tumor-immune interactions and the evaluation of immunotherapies. This approach more accurately mirrors the complex dynamics of human immune responses to tumors. As immunotherapy gains traction as a groundbreaking avenue for cancer treatment, pharmaceutical and biotech companies seek in vivo CROs with specialized expertise in syngeneic models. These CROs offer the capacity to assess the efficacy and safety of novel immunotherapies, predict potential side effects, and optimize treatment strategies. By closely replicating the human immune system's responses to tumors, syngeneic models are playing a pivotal role in advancing immunotherapy research and shaping the trajectory of oncology based CRO services.


Download free Sample Report

Regional Insights

The North America region has established itself as the leader in the Oncology Based In-vivo CRO Market with a significant revenue share of 37% in 2022. 

Recent Developments

  • To enhance the commercialization and development of the OmniCAR cell therapy technology, Thermo Fisher Scientific Inc. and Prescient Therapeutics established a partnership in August 2022. This agreement would evaluate the potential of using automated closed-cell therapy options to develop a special method for making cell treatments on the OmniCAR platform without the usage of viruses.
  • Elicio Therapeutics received a USD 2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago in September 2022 to support the development of two therapeutic cancer vaccines. While ELI-008 is being developed to target p53 hotspot mutations in solid tumours such colorectal cancer, melanoma, and non-small cell lung cancer (NSCLC), ELI-007 is being developed to target BRAF gene alterations. As a result, the COVID-19 pandemic has influenced the in-vivo CRO market for oncology.
  • Bioanalytical Systems, Inc. debuted Inotiv, its new brand for contract research services, in November 2021. Beginning with in vivo toxicology, pharmacology, bioanalysis, drug metabolism, and pharmacokinetic solutions, Inotiv began representing the unification of the business' Seventh Wave Laboratories & Smithers Avanza Toxicology Services.

Key Market Players

  • Charles River Laboratories, Inc.
  • ICON PLC
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific SE
  • Taconic Biosciences, Inc.
  • Crown Biosciene, Inc.
  • LabCorp
  • WuXi AppTec Co., Ltd.
  • Evotec SE
  • The Jackson Laboratory

By Indication

By Model

By Region
  • Blood Cancer
  • Solid Tumor
  • Syngeneic Model
  • Patient Derived Xenograft
  • Xenograft
  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East & Africa

 


Report Scope:

In this report, the Oncology Based In-vivo CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Oncology Based In-vivo CRO Market, By Indication:

o   Blood Cancer

o   Solid Tumor

  • Oncology Based In-vivo CRO Market, By Model:

o   Syngeneic Model

o   Patient Derived Xenograft

o   Xenograft

  • Oncology Based In-vivo CRO Market, By Region:

o   North America

o   Europe

o   South America

o   Asia Pacific

o   Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Oncology Based In-vivo CRO Market.

Available Customizations:

Oncology Based In-vivo CRO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Oncology Based In-vivo CRO Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validations

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Oncology Based In-vivo CRO Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Indication (Blood Cancer, Solid Tumor)

5.2.2.    By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft)

5.2.3.    By Region

5.2.4.    By Company (2022)

5.3.  Market Map

6.    North America Oncology Based In-vivo CRO Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Indication

6.2.2.    By Model

6.2.3.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Oncology Based In-vivo CRO Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.            By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.            By Indication

6.3.1.2.2.            By Model

6.3.2.    Canada Oncology Based In-vivo CRO Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.            By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.            By Indication

6.3.2.2.2.            By Model

6.3.3.    Mexico Oncology Based In-vivo CRO Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.            By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.            By Indication

6.3.3.2.2.            By Model

7.    Europe Oncology Based In-vivo CRO Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Indication

7.2.2.    By Model

7.2.3.    By Country

7.3.  Europe: Country Analysis

7.3.1.    Germany Oncology Based In-vivo CRO Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Indication

7.3.1.2.2.            By Model

7.3.2.    United Kingdom Oncology Based In-vivo CRO Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Indication

7.3.2.2.2.            By Model

7.3.3.    Italy Oncology Based In-vivo CRO Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecasty

7.3.3.2.1.            By Indication

7.3.3.2.2.            By Model

7.3.4.    France Oncology Based In-vivo CRO Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.            By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.            By Indication

7.3.4.2.2.            By Model

7.3.5.    Spain Oncology Based In-vivo CRO Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.            By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.            By Indication

7.3.5.2.2.            By Model

8.    Asia-Pacific Oncology Based In-vivo CRO Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Indication

8.2.2.    By Model

8.2.3.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Oncology Based In-vivo CRO Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Indication

8.3.1.2.2.            By Model

8.3.2.    India Oncology Based In-vivo CRO Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Indication

8.3.2.2.2.            By Model

8.3.3.    Japan Oncology Based In-vivo CRO Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Indication

8.3.3.2.2.            By Model

8.3.4.    South Korea Oncology Based In-vivo CRO Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Indication

8.3.4.2.2.            By Model

8.3.5.    Australia Oncology Based In-vivo CRO Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Indication

8.3.5.2.2.            By Model

9.    South America Oncology Based In-vivo CRO Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Indication

9.2.2.    By Model

9.2.3.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Oncology Based In-vivo CRO Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Indication

9.3.1.2.2.            By Model

9.3.2.    Argentina Oncology Based In-vivo CRO Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Indication

9.3.2.2.2.            By Model

9.3.3.    Colombia Oncology Based In-vivo CRO Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Indication

9.3.3.2.2.            By Model

10.  Middle East and Africa Oncology Based In-vivo CRO Market Outlook

10.1.   Market Size & Forecast         

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Indication

10.2.2. By Model

10.2.3. By Country

10.3.   MEA: Country Analysis

10.3.1. South Africa Oncology Based In-vivo CRO Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Indication

10.3.1.2.2.         By Model

10.3.2. Saudi Arabia Oncology Based In-vivo CRO Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Indication

10.3.2.2.2.         By Model

10.3.3. UAE Oncology Based In-vivo CRO Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Indication

10.3.3.2.2.         By Model

11.  Market Dynamics

11.1.   Drivers

11.2.   Challenges

12.  Market Trends & Developments

12.1.   Recent Development

12.2.   Mergers & Acquisitions

12.3.   Treatment Type Launches

13.  Global Oncology Based In-vivo CRO Market: SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.   Competition in the Industry

14.2.   Potential of New Entrants

14.3.   Power of Suppliers

14.4.   Power of Customers

14.5.   Threat of Substitute Treatment Types

15.  Competitive Landscape

15.1.   Business Overview

15.2.   Service Offerings

15.3.   Recent Developments

15.4.   Key Personnel

15.5.   SWOT Analysis

15.5.1. Charles River Laboratories, Inc.

15.5.2. ICON PLC

15.5.3. Thermo Fisher Scientific Inc.

15.5.4. Eurofins Scientific SE

15.5.5. Taconic Biosciences, Inc.

15.5.6. Crown Biosciene, Inc.

15.5.7. LabCorp

15.5.8. WuXi AppTec Co., Ltd.

15.5.9. Evotec SE

15.5.10.               The Jackson Laboratory

16.  Strategic Recommendations

17.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Oncology Based In-vivo CRO Market was estimated to be USD 1.24 Billion in 2022.

down-arrow

The oncology-based in-vivo CRO market is dominated by the solid tumours category with a 47.08% market share in 2022, and it is anticipated that this trend will continue. Due of their common occurrence and intricate makeup, solid tumours have been the market's major in vivo oncology players. The demand for specialised research services offered by in vivo CROs is driven by the tumours that are distinguished by their cohesive mass of cells and account for a sizable fraction of cancer cases.

down-arrow

Due to its strong research infrastructure, sophisticated healthcare ecosystem, and concentration of pharmaceutical and biotechnology firms, the North American area has become a dominant force in the oncology-based in vivo Contract Research Organisation (CRO) industry. North America provides a favourable environment for cutting-edge cancer research thanks to its wide network of academic institutions, research centres, and state-of-the-art medical facilities.

down-arrow

Increasing cancer prevalence is the major driver for the Oncology Based In-vivo CRO Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Oncology Based In-vivo CRO Market to be dominated by Solid Tumor through 2028

Sep, 2023

Increasing prevalence of cancer is driving the growth of Oncology Based In-vivo CRO market in the forecast period 2024-2028.

Why Choose Us